TLR7 · Western blot design guide

TLR7 Western Blot Planning Guide

Plan a TLR7 Western blot around the catalog-observed 120.9 kDa band, image-backed PA1733 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for TLR7 (TLR7): expected band 120.9 kDa, antibody PA1733, and guide-derived SDS-PAGE protocol steps
TLR7 Western blot protocol sheet — expected band 120.9 kDa, antibody PA1733, controls and PMC citations. Open the full TLR7 WB guide →

TLR7 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 120.9 kDa
Observed band Not reported — verify product WB image
Gel 8-10%
Positive control ⓘ Skin
Negative control ⓘ Breast
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 120.9 kDa
ⓘ Localization Endoplasmic reticulum membrane / Endosome
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated TLR7 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateSkin
Gel %8-10%
Load20-30 µg total protein per lane
TransferWet/tank, extended transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryPA1733 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected TLR7 Western Blot Band Size?

Use the product-observed 120.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
120.9 kDaMatches the authoritative product WB observation.
120.9 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected TLR7 appearancePlan around 120.9 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band120.9 kDa; use this as the primary experimental expectation.
Calculated mass120.9 kDa from UniProt Q9NYK1; retain as context.
Gel selection8-10%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with PA1733.
Why is my band missing or off?
SituationLikely causeNext action
120.9 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for TLR7 Western blot

🧪Use Skin as the first positive-control candidate and Breast as the HPA Not detected negative candidate.
Positive control: Skin (High)
Negative control: Breast (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for TLR7

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Skin Reported tissue cells High Protein (HPA) HPA →
Spleen Reported tissue cells Medium Protein (HPA) HPA →
Appendix Reported tissue cells Medium Protein (HPA) HPA →
Cerebellum Reported tissue cells Medium Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Breast Reported tissue cells Not detected Protein (HPA) HPA →
Bronchus Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced TLR7 Western Blot Tips

Deeper troubleshooting and optimisation questions for TLR7, answered from its protein features.

Which band should guide the blot?
Use 120.9 kDa, the observation attached to the authoritative PA1733 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 120.9 kDa expectation.
Which positive control should I start with?
Start with Skin, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Breast as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for TLR7 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA1733 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

TLR7 Western Blot Reagents

Human/Mouse/Rat-reactive TLR7 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for TLR7 using PA1733; observed band 120.9 kDa
Anti-Toll-like receptor 7 TLR7 Antibody Picoband®
Cat # PA1733
Real WB data Western blot validation image for TLR7 using PB9452; observed band 120.9 kDa
Anti-TLR7 Antibody Picoband®
Cat # PB9452

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt Q9NYK1
  2. Human Protein Atlas — TLR7
  3. PA1733 product record
  4. PMC5325409 — Lipid rafts promote liver cancer cell proliferation and migration by up-regulation of TLR7 expression (Oncotarget, 2016)
  5. PMC8899919 — Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis (EMBO molecular medicine, 2022)
  6. PMC11589596 — Promotion of TLR7-MyD88-dependent inflammation and autoimmunity in mice through stem-loop changes in Lnc-Atg16l1 (Nature communications, 2024)